Huntsman Ronald Kirk
Known title: Chief Executive OfficerCIK: 0001835498
Huntsman Ronald Kirk's purchase track record
How the stock did after each of Huntsman Ronald Kirk's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since September 21, 2021
Stock higher 6 months later
25%
3 months: 0%
Median 6-month return
-23.2%
3 months: -37.4%
Beat the S&P 500
0%
median -28.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/14/2023 | VVOS | $20K | -48.9% | -8.6% | +7.6% |
| 12/23/2022 | VVOS | $10K | -27.9% | +1.5% | +13.1% |
| 5/31/2022 | VVOS | $24K | -38.4% | -73.9% | -4.2% |
| 9/21/2021 | VVOS | $22K | -36.4% | -37.8% | +3.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VVOS | ▼ Sell | Other | 85,910 | $50K | 6/30/2026 | View on chart |
| VVOS | ▲ Buy | Open Market | 14,000 | $7K | 6/20/2023 | View on chart |
| VVOS | ▲ Buy | Open Market | 10,000 | $5K | 6/16/2023 | View on chart |
| VVOS | ▲ Buy | Open Market | 5,000 | $3K | 6/16/2023 | View on chart |
| VVOS | ▲ Buy | Open Market | 21 | $11 | 6/15/2023 | View on chart |
| VVOS | ▲ Buy | Open Market | 10,000 | $5K | 6/14/2023 | View on chart |
| VVOS | ▲ Buy | Open Market | 20,000 | $10K | 12/23/2022 | View on chart |
| VVOS | ▲ Buy | Open Market | 4,000 | $7K | 6/1/2022 | View on chart |
| VVOS | ▲ Buy | Open Market | 8,000 | $16K | 5/31/2022 | View on chart |
| VVOS | ▲ Buy | Open Market | 5,000 | $22K | 9/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
VVOS Announces $3.6M Annual Cost‑Reduction Plan
Vivos Therapeutics disclosed a restructuring plan that aims to cut annual costs by $3.6 million beginning in the fourth quarter of 2026. The company also reported progress on material cost reductions and initiatives to grow revenue. These actions are intended to improve financial efficiency while supporting ongoing growth efforts.
VVOS Announces $3.6M Annual Cost‑Reduction Plan. Vivos Therapeutics disclosed a restructuring plan that aims to cut annual costs by $3.6 million beginning in the fourth quarter of 2026. The company also reported progress on material cost reductions and initiatives to grow revenue. These actions are intended to improve financial efficiency while supporting ongoing growth efforts.